| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense) | 45,705 | 5,218 | ||
| Loss before income tax expense | -11,183 | -36,717 | ||
| Income tax (expense) benefit | 0 | 0 | ||
| Net loss | -11,183 | -327 | ||
| Net loss per share, basic (in dollars per share) | - | -19.62 | ||
| Net loss per share, diluted (in dollars per share) | - | -19.62 | ||
| Weighted-average common stock outstanding, basic (in shares) | - | 16,667 | ||
| Weighted-average common stock outstanding, diluted (in shares) | - | 16,667 | ||
| Net loss per share, basic (in dollars per share) | -5.97 | - | ||
| Net loss per share, diluted (in dollars per share) | -5.97 | - | ||
| Weighted-average common stock outstanding, basic (in shares) | 346,045 | - | ||
| Weighted-average common stock outstanding, diluted (in shares) | 346,045 | - | ||
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)